当前位置： SCI文献检索 > Experimental and Therapeutic Medicine期刊下所有文献 > ERCC1 protein as a guide for individualized therapy of late-stage advanced non-small cell lung cancer.

ERCC1 protein as a guide for individualized therapy of late-stage advanced non-small cell lung cancer.

Abstract：

:Excision repair cross-complementation group 1 (ERCC1) protein has been associated with cisplatin resistance. The objective of this study was to investigate the correlation between ERCC1 protein levels and the therapeutic effect of individualized therapy in advanced non-small cell lung cancer (NSCLC). A total of 190 advanced NSCLC patients were included in this study. Patients were randomized into either the individualized therapy group or the standard therapy group at a ratio of 2:1. Patients in the standard therapy group were treated with either gemcitabine plus cisplatin or vinorelbine plus cisplatin. The expression of ERCC1 protein in lung cancer tissues of patients from the individualized therapy group was detected with immunohistochemistry. Patients with low ERCC1 levels received either gemcitabine plus cisplatin or vinorelbine plus cisplatin, and patients with high levels received gemcitabine plus vinorelbine. The main outcome assessments were response rate (RR), overall survival (OS) and time to progression (TTP). Follow-up data were recorded until September 30, 2010. RR, 1-year survival rate and TTP were not statistically significant. The median survival time was 10.10 months in the standard therapy group (95% CI 8.48-11.92) and 13.59 months in the individualized therapy group (95% CI 11.86-14.74). The difference in median survival time was significantly different between these groups (P=0.036). The median survival time was longer in the individualized group compared to the standard therapy group. ERCC1 protein expression in advanced NSCLC patients, however, was not significantly correlated with RR, OS and TTP in the individualized therapy group. Therefore, this study suggests that ERCC1 protein levels should be assessed in combination with additional biomarkers to determine an optimal index for individualized therapy in advanced NSCLC patients.

journal_name

Exp Ther Med

journal_title

Experimental and therapeutic medicine

authors

Gao Z,Han B,Shen J,Gu A,Qi D,Huang J,Shi C,Xiong L,Zhao Y,Jiang L,Wang H,Chen Y

doi

10.3892/etm.2011.276

subject

Has Abstract

pub_date

2011-09-01 00:00:00

pages

811-815

issue

eissn

1792-0981

issn

1792-1015

pii

etm-02-05-0811

journal_volume

pub_type

杂志文章

在线工具

ERCC1 protein as a guide for individualized therapy of late-stage advanced non-small cell lung cancer.